

Distribution of *erm* genes among *Staphylococcus aureus* isolates with inducible resistance to clindamycin in Isfahan, Iran

Fahimeh Ghanbari, Hasan Ghajavand¹, Roholla Havaei², Mohammad-Saeid Jami³, Farzad Khademi⁴, Leila Heydari, Mojtaba Shahin⁵, Seyed Asghar Havaei¹

Departments of Microbiology, Faculty of Bioscience, Falavarjan Branch, Islamic Azad University, ¹School of Medicine, Isfahan University of Medical Sciences, Isfahan, ²Department of Endodontics, School of Dentistry, Zahedan University of Medical Sciences, Zahedan, ³Cellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, ⁴Department of Medical Bacteriology and Virology, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, ⁵Department of Microbiology, School of Medicine, Ahvaz University of Medical Sciences, Ahvaz, Iran

Abstract

Background: The rising frequency of methicillin resistant *Staphylococcus aureus* (MRSA) has led to an increased use of antibiotics such as macrolide, lincosamide, streptogramin B (MLS_B) for the treatment of *S. aureus* infections. Resistance to MLS_B in *S. aureus* is commonly encoded by *erm* genes, which can be constitutive MLS_B (cMLS_B) or inducible MLS_B (iMLS_B). The purpose of this study was to determine the frequency of cMLS_B, iMLS_B, and MS phenotypes using D-test and polymerase chain reaction (PCR) methods.

Materials and Methods: A total of 215 isolates of *S. aureus* were collected from January 2010 to May 2012 from Al-Zahra Hospital in Isfahan. PCR was performed for detection of *mecA* gene on all isolates using specific primers. The frequency of MLS_B-resistant isolates was determined using D-test, and then a multiplex PCR was performed for detection of *ermA*, *ermB*, and *ermC* genes.

Results: Among 215 *S. aureus* isolates examined, 82 (40.9%) were MRSA, and iMLS_B, cMLS_B, and MS resistance phenotypes had a frequency of 9 (4.18%), 58 (26.9%), and 11 (5.1%), respectively. Among nine isolates with iMLS_B resistance phenotype, four isolates contained *ermC* gene, two isolates *ermB* gene, and one isolate *ermA* gene. Two isolates did not have any *erm* gene.

Conclusion: In the current study, cMLS_B was the most frequent phenotype and *ermC* was the most common gene in iMLS_B resistant phenotypes.

Key Words: Clindamycin, D-test, *erm* genes, inducible resistance, *Staphylococcus aureus*

Address for correspondence:

Dr. Seyed Asghar Havaei, Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

E-mail: havaei@med.mui.ac.ir

Received: 30.11.2014, Accepted: 24.05.2015

INTRODUCTION

Staphylococcus aureus is one of the most frequent pathogens that cause both community and

hospital-acquired infections worldwide. Development of drug resistance in *S. aureus* has led to the use of older antibiotics such as macrolide, lincosamide, and streptogramin B (MLS_B) antibiotic.^[1,2] However,

Access this article online	
Quick Response Code:	Website: www.advbiores.net
	DOI: 10.4103/2277-9175.179184

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Ghanbari F, Ghajavand H, Havaei R, Jami MS, Khademi F, Heydari L, *et al.* Distribution of *erm* genes among *Staphylococcus aureus* isolates with inducible resistance to clindamycin in Isfahan, Iran. *Adv Biomed Res* 2016;5:62.

extensive use of these antibiotics in serious staphylococcal infections has caused the emergence of *S. aureus* resistant to MLS_B antibiotics.^[3] There are three different mechanisms of resistance to MLS_B antibiotics including: (1) Active efflux mechanism encoded by *msr* gene, (2) drug inactivation encoded by *lun* gene and (3) ribosomal binding site modification (by methylation or mutation in the 23s *rRNA* gene) encoded by *erm* genes (*ermA*, *ermB*, *ermC*, and *ermF*) among which, *ermA* and *ermC* are predominant genes responsible for resistance to MLS_B antibiotics in staphylococci, which can be constitutive or inducible.^[4-8] *In vitro*, *S. aureus* isolates with constitutive MLS_B (cMLS_B) resistance are resistant to erythromycin and clindamycin but isolates with inducible MLS_B (iMLS_B) resistance are resistant to erythromycin and susceptible to clindamycin. In this condition, treatment of patients with clindamycin can lead to the emergence of resistant mutants to cMLS_B from iMLS_B-resistant strains and treatment failure.^[3,6] On the other hand, assigning all erythromycin-resistant *S. aureus* as clindamycin resistant strains may cause to avoid the use of clindamycin in the treatment of *S. aureus* infections. For this reason, careful screening of iMLS_B-resistant strains is very important. While constitutive resistance is detectable by routine antimicrobial susceptibility tests, inducible resistance to clindamycin is not detectable by standard methods.^[4,5] For detection of iMLS-resistant strains, Clinical and Laboratory Standards Institute (CLSI) developed a phenotypic method called the double disk diffusion test (D-test).^[9-12] The aim of this study was to determine the frequency of inducible resistance to clindamycin using D-test and polymerase chain reaction (PCR) with specific primers to confirm the presence of the *erm* genes in these isolates.

MATERIALS AND METHODS

Bacterial strains and phenotypic testing

A total of 215 clinical isolates of *S. aureus* were collected from Al-Zahra Hospital in Isfahan from January 2010 to May 2012. Bacterial isolates were obtained from various clinical specimens including: Wound, blood, urine, sputum, etc., Early identification was performed based on Gram-staining and positive biochemical reactions such as catalase, coagulase, and DNase tests. D-test method was performed according to the CLSI guidelines using clindamycin (2 µg) and erythromycin (15 µg) disks (Himedia-India). For this purpose, suspensions of bacteria were prepared in the sterile saline (2 ml) equivalent to standard 0.5 McFarland and then two antibiotic disks placed on Muller-Hinton agar media in 15 mm distance (edge-to-edge). Plates were incubated at 35°C overnight. Strains with flat zone of growth

inhibition of clindamycin near the erythromycin disk (D-shape) were classified as resistant phenotypes to iMLS_B (D-test positive), while those with a circular zone were classified as MS resistant phenotypes (D-test negative) [Figure 1].

Molecular detection of *mecA* gene

DNA was extracted from 215 *S. aureus* isolates using Fermentas K0512 DNA kit (Fermentas-USA) in accordance with the manufacturer's protocol. PCR reaction was carried out for the amplification of the 310 bp fragment of *mecA* gene using primers as exhibited in Table 1. PCR amplification reaction mixture (25 µL) contained 4 µL of DNA template, 2.5 µL of PCR buffer (×10), 0.75 µL MgCl₂ (50 mM), 0.5 µL of dNTPs (10 mM), 1 µL of each primers (2 µL totally), 0.25 µL of Ex-Taq DNA polymerase (5u/µL) and 15 µL distill water. PCR conditions were as follows: Initial denaturation at 94°C for 5 min, 30 cycles of denaturation at 94°C for 30 s, annealing at 55°C for 30 s and extension at 72°C for 30 s, and final extension at 72°C for 7 min.

Multiplex polymerase chain reaction for *erm* gene

Multiplex PCR was performed for detection of *erm* gene in D-test positive isolates using specific primers for the *ermA*, *B* and *C* genes as exhibited in Table 1. Each PCR was performed in a final volume of 25 µL consisting of 5 µL of DNA template, 2.5 µL of PCR buffer (×10), 1 µL MgCl₂ (50 mM), 0.5 µL of dNTPs (10 mM), 0.75 µL of each primers (2 µL totally), 0.25 µL of Ex-Taq DNA polymerase (5 u/µL), 11.25 µL distill water. DNA was amplified on a thermocycler (Ependorf-Germany), and PCR conditions were as follows: Initial denaturation at 94°C for 10 min, 35 cycles of denaturation at 94°C for 30 s, annealing at 53°C for 30 s, and extension at 72°C for 60 s, followed by a final extension at 72°C for 10 min.



Figure 1: D-shape zone of growth inhibition around clindamycin disk (inducible macrolide, lincosamide, streptogramin B phenotype)

RESULTS

In this study, 215 isolates of *S. aureus* were collected from various clinical specimens, wound 53 (24.6%), blood 49 (22.79%), urinary tract infection 30 (13.9%), sputum 35 (16.27%), abscess 21 (9.76) and others 27 (12.55%), from Al-Zahra Hospital in Isfahan. The patient's average age was 47 years (ranged 1–88 years). The *mecA* gene screening in all isolates showed that 82 (40.9%) of the 215 tested isolates were methicillin resistant *S. aureus* (MRSA) and *mecA* positive [Figure 2]. Furthermore, double disk diffusion test results revealed that 134 (62.3%) of the isolates were susceptible to both clindamycin and erythromycin and 81 (37.7%) were shown to have four different resistance phenotypes in which 58 (26.9%) isolates were resistant phenotype to cMLS_B (resistant to both erythromycin and clindamycin), 9 (4.18%) isolates were resistant phenotype to iMLS_B (resistant to erythromycin and susceptible to clindamycin), 11 (5.1%) isolates were MS resistance phenotype (susceptible to clindamycin and resistant to erythromycin) and finally, 3 (1.39%) isolates were susceptible to erythromycin and resistant to clindamycin [Figure 3]. Among nine isolates with

iMLS_B resistance phenotype, 5 (55.5%) were MRSA. Nine staphylococcal isolates with iMLS_B resistance phenotype were tested for the presence of the *erm* genes, the *ermA* gene in 1 (11.1%) isolate, the *ermB* gene in 2 (22.2%) isolates, the *ermC* gene in 4 (44.4%) isolates was detected and two isolates did not have any *erm* genes [Figure 3].

DISCUSSION

D-test results in our study demonstrated that 134 (62.3%) isolates were sensitive to both erythromycin and clindamycin; the frequency of cMLS_B, iMLS_B, and MS phenotypes were found to be 58 (26.9%), 9 (4.18%), and 11 (5.1%), respectively. In addition, the frequency of *ermC*, *ermB*, and *ermA* genes among isolates with iMLS_B phenotype was determined to be 44.4%, 22.2%, and 11.1% respectively. Clindamycin due to its advantages including low-cost, low side effects, and good tissue penetration is used for the treatment of *S. aureus* infections. Although it is a good alternative in allergic patients instead of β-lactam antibiotics;^[1,9,14,15] however, excessive use of this antibiotic has an important role in bacterial resistance to clindamycin. Since the treatment of infected patients with resistant strains to iMLS_B can lead to the expansion of constitutive resistance (cMLS_B) and therapy failure with clindamycin, detection of resistant strains to iMLS_B is important from other resistance phenotypes. Since the frequency of cMLS_B, iMLS_B, and MS phenotypes varies in different geographical areas, even among different hospitals, awareness of regional frequency of MLS_B resistant isolates is important for laboratories to decide for performing the D-test routinely or reporting all erythromycin-resistant *S. aureus* as clindamycin resistant.^[7,10,12,16]

Table 1: Primers used in this study

Target Sequence	Product size (bp)	References
<i>ermA</i> GTTCAAGAAC AATCAATACAGAG GGATCAGGAA AAGGACATTTTAC	421	[13]
<i>ermB</i> CCGTTTACGA AATTGGAACA GGTAAGGGC GAATCGAGAC TTGAGTGTGC	359	[13]
<i>ermC</i> GCTAATATTG TTTAAATCGT CAATTCC GGATCAGGAA AAGGACATTT TAC	572	[13]
<i>mecA</i> AAAATCGATGGTAAAGGTTGGC AGTTCTGCAGTACCGGATTTG	310	[14]




Figure 2: Gel electrophoresis of *mecA* gene. Lanes 1–5: 310 bp fragment, Lane 6: positive control of methicillin resistant *Staphylococcus aureus* strains ATCC 33591, Lane 7: DNA Ladder 100 bp




Figure 3: Gel electrophoresis of *erm* genes. Lane 1: *ermA* positive (421 bp), Lane 2 and 3: *ermB* positive (359 bp), Lane 4: *ermC* positive (572 bp), Lane 5: DNA Ladder 100 bp

In the current study, 82 (40.9%) isolates were found to be MRSA that is, comparable with a study conducted by Seifi *et al.*^[5] Also, 6.09% of MRSA isolates had resistant phenotype to iMLS_B, which is lower than those reported by Shoja *et al.*^[17] In the current study, 134 (62.3%) isolates were sensitive to both erythromycin and clindamycin and the frequency of cMLS_B, iMLS_B and MS phenotypes were found to be 58 (26.9%), 9 (4.18%), and 11 (5.1%) respectively. Similar results were reported by Aslanimehr *et al.*^[18] In the present study, the frequency of cMLS_B phenotype was higher than iMLS_B phenotype. Similar results were obtained by Memarian *et al.*^[19] and Mahesh *et al.*^[20] In contrast, Reddy and Suresh found the frequency of iMLS_B phenotype to be higher than cMLS_B phenotype.^[3] In our study, the frequency of MS resistance phenotype was shown to be higher than iMLS_B phenotype, which was concordant to some previous studies.^[3,5,7] Incidentally, we detected 3 (1.39%) isolates resistant to clindamycin and susceptible to erythromycin, similar results were also obtained by Coutinho *et al.*^[10] In addition, Seifi *et al.* reported 6 (2.84%) *S. aureus* isolates with such a phenotype.^[5] This phenotype can be created by lincosamide nucleotide transferase enzyme that only inactivates lincosamide (clindamycin). Therefore, we investigated *erm* gene distribution among isolates with iMLS_B phenotype. Our results revealed the frequency of *ermC*, *ermB*, and *ermA* genes among isolates with iMLS_B phenotype to be 44.4%, 22.2%, and 11.1%, respectively. Two isolates with iMLS_B phenotype were negative in genotypic test.

It must be noted that the frequency of *erm* genes is variable in different studies. According to our findings, the *ermC* gene was the most prevalent gene, similar study was performed by Aktas *et al.* in Turkey,^[7] while in a study conducted by Saderi *et al.* *ermA* gene was prevalent (60%) among erythromycin-resistant *S. aureus*.^[2] An interesting point to notice in our study was the high frequency of *ermB* gene, Similar results were shown in some studies.^[21,22]

CONCLUSION

This report has investigated the frequency of inducible resistance to clindamycin using D-test and PCR methods. This was the first study to investigate the frequency of MLS_B phenotypes in Isfahan which demonstrated cMLS_B resistance to be the most prevalent resistance phenotype, *ermC* gene as the most common gene among iMLS-resistant *S. aureus* and iMLS_B phenotype having a low frequency. Therefore, we do not recommend the routine performance of D-test but since the frequency of different resistance phenotype may change through time with the emergence of strains with different antibiotic

susceptibility patterns, it is recommended that local periodic survey be performed.

Financial support and sponsorship

Nil.


Conflicts of interest

There are no conflicts of interest.

REFERENCES

- Vivek JS, Rajesh GN, Mukesh S, Manpreet K, Manpreet K, Misra RN, *et al.* Prevalence of inducible clindamycin resistance among community- and hospital-associated *Staphylococcus aureus* isolates in a tertiary care hospital in India. *Biomed Res* 2011;22:465-9.
- Saderi H, Emadi B, Owlia P. Phenotypic and genotypic study of macrolide, lincosamide and streptogramin B (MLS_B) resistance in clinical isolates of *Staphylococcus aureus* in Tehran, Iran. *Med Sci Monit* 2011;17:BR48-53.
- Reddy SP, Suresh R. Phenotypic detection of inducible clindamycin resistance among the clinical isolates of *staphylococcus aureus* by using the lower limit of inter disk space. *J Microbiol Biotechnol Res* 2012;2:258-64.
- Zelazny AM, Ferraro MJ, Glennen A, Hindler JF, Mann LM, Munro S, *et al.* Selection of strains for quality assessment of the disk induction method for detection of inducible clindamycin resistance in staphylococci: A CLSI collaborative study. *J Clin Microbiol* 2005;43:2613-5.
- Seifi N, Kahani N, Askari E, Mahdipour S, Naderi NM. Inducible clindamycin resistance in *Staphylococcus aureus* isolates recovered from Mashhad, Iran. *Iran J Microbiol* 2012;4:82-6.
- Steward CD, Raney PM, Morrell AK, Williams PP, McDougal LK, Jevitt L, *et al.* Testing for induction of clindamycin resistance in erythromycin-resistant isolates of *Staphylococcus aureus*. *J Clin Microbiol* 2005;43:1716-21.
- Aktas Z, Aridogan A, Kayacan CB, Aydin D. Resistance to macrolide, lincosamide and streptogramin antibiotics in staphylococci isolated in Istanbul, Turkey. *J Microbiol* 2007;45:286-90.
- Schmitz FJ, Sadurski R, Kray A, Boos M, Geisel R, Köhrer K, *et al.* Prevalence of macrolide-resistance genes in *Staphylococcus aureus* and *Enterococcus faecium* isolates from 24 European university hospitals. *J Antimicrob Chemother* 2000;45:891-4.
- Fiebelkorn KR, Crawford SA, McElmeel ML, Jorgensen JH. Practical disk diffusion method for detection of inducible clindamycin resistance in *Staphylococcus aureus* and coagulase-negative staphylococci. *J Clin Microbiol* 2003;41:4740-4.
- Coutinho Vde L, Paiva RM, Reiter KC, de-Paris F, Barth AL, Machado AB. Distribution of *erm* genes and low prevalence of inducible resistance to clindamycin among staphylococci isolates. *Braz J Infect Dis* 2010;14:564-8.
- Sedighi I, Yousefi Mashouf R, Pak N, Seif Rabiee MA. D-test method for detection of inducible clindamycin resistance in *Staphylococcus aureus*. *Iran J Pediatr* 2009;19:293-7.
- O'Sullivan MV, Cai Y, Kong F, Zeng X, Gilbert GL. Influence of disk separation distance on accuracy of the disk approximation test for detection of inducible clindamycin resistance in *Staphylococcus spp.* *J Clin Microbiol* 2006;44:4072-6.
- Lina G, Quaglia A, Reverdy ME, Leclercq R, Vandenesch F, Etienne J. Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci. *Antimicrob Agents Chemother* 1999;43:1062-6.
- Lim HS, Lee H, Roh KH, Yum JH, Yong D, Lee K, *et al.* Prevalence of inducible clindamycin resistance in staphylococcal isolates at a Korean tertiary care hospital. *Yonsei Med J* 2006;47:480-4.
- Schreckenberger PC, Ilendo E, Ristow KL. Incidence of constitutive and inducible clindamycin resistance in *Staphylococcus aureus* and coagulase-negative staphylococci in a community and a tertiary care hospital. *J Clin Microbiol* 2004;42:2777-9.
- Lewis JS 2nd, Jorgensen JH. Inducible clindamycin resistance in

- Staphylococci*: Should clinicians and microbiologists be concerned? *Antimicrob Resist* 2005;40:280-5.
17. Shoja S, Nahaei M, Nahaei M. Detection of inducible clindamycin resistance in *Staphylococcus aureus* and *Staphylococcus epidermidis* by using D-test. *Pharma Sci* 2009;15:1-8.
 18. Aslanimehr M, Yaghobfar R, Peymani A. Detection of MLSB phenotypes and inducible clindamycin resistance in *Staphylococcus aureus* isolates in-patients of Qazvin and Tehran teaching hospitals. *J Qazvin Univ Med Sci* 2014;18:30-6.
 19. Memariani M, Pourmand MR, Shirazi MH, Soltan Dallal MM, Abdolsamadi Z, Mardani N. The importance of inducible clindamycin resistance in enterotoxin positive *S. aureus* isolated from clinical samples. *Tehran Univ Med J* 2009;67:250-6. [Persian]
 20. Mahesh CB, Ramakant BK, Jagadeesh VS. The prevalence of inducible and constitutive clindamycin resistance among the nasal isolates of staphylococci. *J Clin Diagn Res* 2013;7:1620-2.
 21. Emaneini M, Eslampour MA, Sedaghat H, Aligholi M, Jabalameli F, Shahsavan S, *et al.* Characterization of phenotypic and genotypic inducible macrolide resistance in staphylococci in Tehran, Iran. *J Chemother* 2009;21:595-7.
 22. Zmantar T, Chaieb K, Ben Abdallah F, Ben Kahla-Nakbi A, Ben Hassen A, Mahdouani K, *et al.* Multiplex PCR detection of the antibiotic resistance genes in *Staphylococcus aureus* strains isolated from auricular infections. *Folia Microbiol (Praha)* 2008;53:357-62.



To,
The Editor

Covering Letter

Submission of Manuscript for publication

Dear Sir,

We intend to publish an article entitled

in your journal.

On behalf of all the contributors I will act and guarantor and will correspond with the journal from this point onward.

Prior presentation of the data reported in this manuscript:

Organisation

Place

Date

We have done sufficient work in the field to justify authorship for this manuscript.

We hereby transfer, assign, or otherwise convey all copyright ownership, including any and all rights incidental thereto, exclusively to the journal, in the event that such work is published by the journal.

Thank you,

Yours' sincerely,

Name of corresponding contributor

Signature

Title of the manuscript:

Title Page

Type of manuscript:

Running title:

Contributors:

	First name	Middle name initial	Last name	Highest academic degree	Names of departments and institutions (including city and state)	Email addresses
1						
2						
3						
4						
5						
6						

Corresponding Author:

Name:

Address:

Phone numbers:

Facsimile numbers:

E-mail address:

Total number of pages:

Total number of tables:

Total number of figures:

Total number of supplementary files:

Word counts: For abstract:

For the text:

Acknowledgement:

Conflict of interest:

Financial Support:

Contribution details (to be ticked marked as applicable):

Contributors' form

	Contributor 1	Contributor 2	Contributor 3	Contributor 4	Contributor 5	Contributor 6
Concepts						
Design						
Definition of intellectual content						
Literature search						
Clinical studies						
Experimental studies						
Data acquisition						
Data analysis						
Statistical analysis						
Manuscript preparation						
Manuscript editing						
Manuscript review						
Guarantor						